comparemela.com

Latest Breaking News On - Harry sloan - Page 27 : comparemela.com

Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $15 billion deal

Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $15 billion deal SECTIONS Last Updated: May 11, 2021, 04:16 PM IST Share Synopsis The deal with Soaring Eagle Acquisition Corp is expected to fetch $2.5 billion in proceeds for the combined entity, the companies said. Baillie Gifford, Putnam Investments and accounts advised by ARK Investment Management have agreed to invest $775 million in the deal. iStock Boston-based Ginkgo is also backed by Bill Gates private investment firm Cascade Investment. Ginkgo Bioworks will go public through a merger with a blank-check company led by former Hollywood executives Harry Sloan and Jeff Sagansky, in a deal that values the biotech company at $15 billion, the companies said on Tuesday.

(SRNG), (BLI) - What Investors Should Know About Ginkgo Bioworks SPAC Deal: Cell Programming Has The Potential To Impact Every Physical Goods Industry

Share: A well seasoned SPAC management team announced a SPAC deal Tuesday to bring a cell programming company public. The SPAC Deal: Ginkgo Bioworks is going public in a SPAC deal with Soaring Eagle Acquisition Corp (NASDAQ: SRNG) that values the company at a pre money equity value of $15 billion. Soaring Eagle Acquisition Corp is a SPAC from Harry Sloan and Jeff Sagansky, a seasoned SPAC team that previously brought DraftKings Inc (NASDAQ: DKNG) and Skillz (NYSE: SKLZ) public. The SPAC merger includes an oversubscribed PIPE of $775 million from key investors that included Baillie Gifford, Bain Capital, T. Rowe Price, Ark Investment Management and Cascade Investment, led by Bill Gates.

Ginkgo Bioworks

A four-day week shortened by Labor Day still brought substantial news in the cannabis sector.  “Even though this week was a shortened trading week, there were still lots of financial deals happening. Cronos Group agreed to a partnership with Gingko Bioworks that could be worth $122. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:

Ginkgo plans a $17 5 billion merger with SPAC that took DraftKings public

Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public Jonathan Saltzman © Scott Eisen Jason Kelly, cofounder and chief executive of Ginkgo Bioworks. Ginkgo Bioworks, one of the hottest biotech startups in Massachusetts, said Tuesday that it plans to go public through a $17.5 billion merger with a so-called blank check company backed by Harry Sloan and Jeff Sagansky, the veteran media industry executives who helped take the Boston sports-betting company DraftKings public last year. Popular Searches The deal values Ginkgo at $15 billion, making the merger one of the biggest of its kind. Ginkgo programs cells to produce new proteins, scents, antibiotics, cannabinoids, and other products for a growing array of industries. Launched in 2008 by five scientists from the Massachusetts Institute of Technology, it now employs about 500 people, most of them in Boston’s Seaport.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.